Checked Nov 19, 2026Start a new check

What was checked

A cancer vaccine just added 9 months to median survival for leukemia patients... on the vaccine alone, median survival was 24 months vs 14.7

Assessment summary

Accurate

The Phase 3 REGAL trial of galinpepimut-S (GPS) showed median overall survival of 24.0 months with the vaccine versus 14.7 months with standard treatment, a difference of exactly 9 months.

Key findings

Model assessments

Assessment summary

The survival figures are supported by initial reports from a 126-patient phase 3 AML trial.biospace.com beckersoncology.com However, the wording overgeneralizes the result to “leukemia patients” and omits that GPS was tested in a specific group of AML patients receiving maintenance monotherapy; the available evidence is topline company-reported data rather than a published full dataset.biospace.com mlq.ai

Claims reviewed

A cancer vaccine added 9 months to median survival for leukemia patients.

Needs context
The reported difference was 9.3 months, with median overall survival of 24.0 versus 14.7 months.biospace.com beckersoncology.com But the trial involved adults with acute myeloid leukemia in second or later remission who were unable or ineligible to undergo allogeneic stem-cell transplantation, not leukemia patients generally.mlq.ai

This claim may mislead readers without added context.

On the vaccine alone, median survival was 24 months versus 14.7 months.

Supported
Reports of the phase 3 REGAL trial state that galinpepimut-S monotherapy produced median overall survival of 24.0 months versus 14.7 months with best available treatment.biospace.com marketwatch.com The results are preliminary topline findings and the full dataset has not yet been published.mlq.ai

Assessment summary

  • The claim accurately reflects the Phase 3 REGAL trial results for the leukemia vaccine galinpepimut-S (GPS).
  • All specific figures cited—the 9-month survival benefit, 24-month median survival with vaccine, and 14.7-month median survival with standard treatment—are directly supported by official trial data from multiple authoritative sources.

Claims reviewed

A cancer vaccine just added 9 months to median survival for leukemia patients

Supported
The Phase 3 REGAL trial of galinpepimut-S (GPS) showed median overall survival of 24.0 months with the vaccine versus 14.7 months with standard treatment, a difference of exactly 9 months mskcc.org fiercebiotech.com targetedonc.com.

On the vaccine alone, median survival was 24 months vs 14.7

Supported
Multiple sources confirm median overall survival was 24.0 months for patients receiving GPS vaccine versus 14.7 months for patients receiving best available treatment (observation, hypomethylating agents, venetoclax, low-dose cytarabine, or combinations) mskcc.org fiercebiotech.com targetedonc.com.

Assessment summary

  • The statement matches recent phase 3 trial reports showing galinpepimut‑S improved median overall survival from 14.7 to 24.0 months, a 9.3‑month absolute difference.
  • Multiple reputable summaries and the trial sponsor reported the same median OS figures and the 9‑month gain.

Claims reviewed

A cancer vaccine just added 9 months to median survival for leukemia patients

Supported
Phase 3 REGAL trial reports state the vaccine (galinpepimut‑S) increased median overall survival by about 9 months versus control, a result presented in recent coverage. mskcc.org medgadget.org

On the vaccine alone, median survival was 24 months vs 14.7

Supported
Published summaries of the REGAL phase 3 trial list median OS of 24.0 months for the vaccine arm and 14.7 months for the comparator arm. mskcc.org medgadget.org

Sources cited

14 sources

Share this result